Acute reversible hypoxemia in systemic lupus erythematosus: a new syndrome or an index of disease activity?

Abstract

In 1991, Abramson et al reported a new syndrome of acute reversible hypoxemia (ARH) in patients with severe SLE (systemic lupus erythematosus). This syndrome was characterized by an unexplained abnormal value of arterial blood gases (ABG) without obvious parenchymal lung disease, and a good response to high-dose corticosteroid therapy. After we became aware of this entity, four of 16 patients admitted to our unit because of a SLE flare presented respiratory symptoms and abnormal ABG consistent with ARH. In none of our patients were the pulmonary manifestations a prominent clinical feature of the disease. Furthermore, in two of them, treatment with high-dose aspirin and moderate to low doses of corticosteroids was sufficient to improve the pulmonary manifestations, but not to control the systemic activity of the disease. Therefore, we believe that this new pulmonary finding more than a clinically independent syndrome represents an index of disease activity in patients with SLE.

Keywords

pulmonary involvement hypoxia complement neutrophils

Get full access to this article

View all access options for this article.

References

Segal AM et al. The pulmonary manifestations of systemic lupus erythematosus . Semin Arthritis Rheum 1985; 14: 202-224.

Silberstein SL et al. Pulmonary dysfunction in systemic lupus erythematosus: prevalence, classification and correlation with other organ involvement. J Rheumatol 1980; 7: 187-195.

Abramson SB et al. Acute reversible hypoxemia in systemic lupus erythematosus. Ann Intern Med 1991; 114: 941-947.

Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.

Hopkins P. et al. Increased levels of plasma anaphylotoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 1988; 31: 632-641.

Abramson SB et al. Neutrophil aggregation induced by sera from patients with active systemic lupus erythematosus. Arthritis Rheum 1983; 26: 630-636.

Jacob HS et al. Complement-induced granulocyte aggregation. An unsuspected mechanism of disease. N Engl J Med 1980; 302: 789-794.

Belmont HM et al. Upregulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Schwartzman phenomenon revisited. Arthritis Rheum 1994; 37: 376-383.

Hammerschmidt DE et al. Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value. Lancet 1980; 1: 947-949.

10.

Arnaout MA et al. Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 1985; 312: 457-462.

11.

Abramson SB , Weissman G. The mechanism of action of non-steroidal anti-inflammatory drugs. Arthritis Rheum 1989 ; 32: 1-9.

12.

Hammerschmidt DE et al. Corticosteroids inhibit complement-induced granulocyte aggregation. J Clin Invest 1979 ; 63: 798-803.